Lifecore Biomedical Stock Price To Book
| LFCR Stock | 6.99 0.01 0.14% |
Fundamental analysis of Lifecore Biomedical allows traders to better anticipate movements in Lifecore Biomedical's stock price by examining its financial health and performance throughout various phases of its business cycle.
As of 08/04/2025, Price To Book Ratio is likely to grow to 0.74. Lifecore | Price To Book | Build AI portfolio with Lifecore Stock |
Lifecore Biomedical Company Price To Book Analysis
Lifecore Biomedical's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Lifecore Biomedical Price To Book | 115.94 X |
Most of Lifecore Biomedical's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lifecore Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Lifecore Biomedical is extremely important. It helps to project a fair market value of Lifecore Stock properly, considering its historical fundamentals such as Price To Book. Since Lifecore Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lifecore Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lifecore Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Lifecore Biomedical has a Price To Book of 115 times. This is 351.49% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to book for all United States stocks is notably lower than that of the firm.
Lifecore Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifecore Biomedical's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics of similar companies.Lifecore Biomedical is currently under evaluation in price to book category among its peers.
Lifecore Biomedical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.Environmental | Governance | Social |
Lifecore Fundamentals
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.0311 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 383.36 M | ||||
| Shares Outstanding | 37.03 M | ||||
| Shares Owned By Insiders | 2.05 % | ||||
| Shares Owned By Institutions | 72.43 % | ||||
| Number Of Shares Shorted | 2.45 M | ||||
| Price To Book | 115.94 X | ||||
| Price To Sales | 1.99 X | ||||
| Revenue | 128.26 M | ||||
| Gross Profit | 43.59 M | ||||
| EBITDA | 35.6 M | ||||
| Net Income | 9.33 M | ||||
| Total Debt | 130.36 M | ||||
| Book Value Per Share | 0.06 X | ||||
| Cash Flow From Operations | (217 K) | ||||
| Short Ratio | 10.48 X | ||||
| Earnings Per Share | (1.47) X | ||||
| Price To Earnings To Growth | 3.51 X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 524 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 258.81 M | ||||
| Total Asset | 273.7 M | ||||
| Retained Earnings | (166.52 M) | ||||
| Working Capital | 42.16 M | ||||
| Net Asset | 273.7 M |
About Lifecore Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lifecore Biomedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.Moving together with Lifecore Stock
| 0.64 | A | Agilent Technologies Earnings Call Today | PairCorr |
Moving against Lifecore Stock
| 0.74 | TELO | Telomir Pharmaceuticals, Earnings Call This Week | PairCorr |
| 0.71 | ERNA | Eterna Therapeutics | PairCorr |
| 0.52 | CLOV | Clover Health Investments Earnings Call Today | PairCorr |
| 0.47 | MOLN | Molecular Partners | PairCorr |
| 0.32 | LPCN | Lipocine | PairCorr |
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.